Cancer Communications (Nov 2022)
Peripheral naïve CD8+ T cells as a predictive biomarker of response to lenvatinib plus an anti‐PD‐1 antibody in advanced hepatocellular carcinoma: a biomarker study
Abstract
No abstracts available.
Cancer Communications (Nov 2022)